Picture of Il Dong Pharmaceutical Co logo

249420 Il Dong Pharmaceutical Co Income Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapNeutral

Annual income statement for Il Dong Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsARSAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue560,132637,714600,758614,941566,934
Cost of Revenue
Gross Profit219,439236,343213,846233,459219,754
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses616,701729,469657,662613,791548,659
Operating Profit-56,569-91,754-56,9041,15018,275
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-141,205-119,823-94,273-10,69231,753
Provision for Income Taxes
Net Income After Taxes-100,968-142,170-80,961-12,40223,698
Minority Interest
Net Income Before Extraordinary Items
Net Income-99,705-141,585-78,928-4,57627,664
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income-99,705-141,585-78,928-4,57628,792
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-4,161-4,917-2,876229844
Dividends per Share